TB-500 Side Effects: What to Expect & Safety Guide UAE (2026)
By Amir Arsalan | CoreSup | Updated March 2026
TB-500 has one of the better safety profiles among research peptides — but "generally well-tolerated" doesn't mean side-effect-free. This guide gives you an honest breakdown of what the research shows, what users actually report, and which populations should avoid it entirely. No sugarcoating, no scare tactics.
For the full picture on what TB-500 does and how it works, see our TB-500 complete guide. For a comparison of TB-500 and BPC-157 safety profiles side by side, read our TB-500 vs BPC-157 comparison.
The Research Baseline: What Studies Say
Most TB-500 safety data comes from its parent compound, Thymosin Beta-4 (TB4). A 2021 review published in preclinical research journals found TB4 well-tolerated and safe in healthy subjects, with no cytotoxicity observed in fibroblast cell cultures. Phase I clinical trials administered high IV doses — up to 5 mcg/kg/day for 10 days — with no serious adverse effects reported.
TB-500 is a synthetic fragment (acetyl-LKKTETQ) of TB4, theoretically safer due to its smaller molecular size and improved bioavailability. The important caveat: no large-scale human RCTs exist specifically for TB-500. Most safety data is extrapolated from TB4 trials, animal studies, and user self-reports.
Common Side Effects (Mild, Dose-Related)
| Side Effect | Frequency | Typical Onset | Duration |
|---|---|---|---|
| Injection site redness/swelling | Most common | Within minutes | 1–4 hours |
| Injection site itching | Common | Within minutes | 1–2 hours |
| Temporary fatigue/lethargy | Common | Within 1–2 hours | 2–6 hours |
| Mild headache | Occasional | Within 2–4 hours | 2–4 hours |
| Mild dizziness | Occasional | Shortly after injection | 30–60 minutes |
| GI discomfort (nausea) | Less common | Variable | 1–3 hours |
These effects are dose-dependent. Users running 2–4mg/week typically report fewer and milder reactions than those front-loading at 8mg/week during the loading phase.
Less Common Side Effects
Some users report effects that are less frequent but worth knowing:
- Skin rash — diffuse redness beyond the injection site, possibly immune-mediated
- Fever or flu-like symptoms — more common if the product has endotoxin contamination (a quality issue, not a TB-500 property per se)
- Muscle aches — occasionally reported in the first 48–72 hours after initial doses
- Mild water retention — some anecdotal reports, possibly related to angiogenesis and improved circulation
- Transient lethargy — observed in animal models at higher doses; some users describe "post-injection tiredness"
Rare but Serious: Hypersensitivity Reactions
Most reported severe reactions appear linked to:
- Repeated exposure — hypersensitivity tends to develop with cumulative injections
- Contaminated product — endotoxins in low-quality peptides trigger inflammatory responses independent of TB-500 itself
- Individual immune sensitivity — people with history of allergic reactions to injected peptides/proteins are at higher risk
For your first injection, consider administering when someone else is present, or at a time when you can monitor for 30–60 minutes.
The Cancer Question: What the Evidence Actually Says
TB-500 promotes angiogenesis — the formation of new blood vessels. This is the mechanism behind much of its healing benefit. But it's also what raises the cancer question: could new blood vessel growth feed existing tumours?
The honest answer: theoretically yes, clinically unconfirmed. No human studies demonstrate TB-500 initiating cancer in healthy individuals. The concern is about people who already have malignant cells that could benefit from increased vasculature. This is why cancer history is a hard contraindication.
TB-500 vs BPC-157: Safety Comparison
| Factor | TB-500 | BPC-157 |
|---|---|---|
| Common side effects | Injection site reactions, fatigue, headache | Injection site reactions, increased appetite |
| Fatigue reports | More frequent | Less frequent |
| Angiogenesis concern | Yes — relevant to cancer contraindication | Minimal angiogenic activity |
| Immune modulation | More pronounced | Less pronounced |
| Human safety data | Phase I/II from TB4 trials | Primarily animal data |
| Cancer contraindication | Strong (angiogenesis) | Moderate (consult required) |
| Overall tolerability | Good in healthy subjects | Good in animal models |
Full Contraindication List
Do not use TB-500 if you:
- Are pregnant or breastfeeding
- Have active or suspected cancer (any type)
- Have a history of anaphylaxis or severe allergic reactions to peptide/protein injections
- Have autoimmune conditions — TB-500 modulates immune function and may exacerbate conditions like lupus, rheumatoid arthritis, or MS
- Have cardiac conditions sensitive to increased fluid volume or vasodilation
- Are under 18
- Have uncontrolled hypertension
How to Minimise Side Effects
- Start low: Begin with 2mg twice per week rather than jumping to the high-end loading dose
- Rotate injection sites: Reduces local irritation and allows tissue recovery
- Use fine gauge: 30–31 gauge needles cause significantly less tissue trauma than 25 gauge
- Verify purity: Most "side effects" from budget peptides are actually endotoxin reactions from poor synthesis — check HPLC certificates
- Inject at room temperature: Cold peptide causes more injection site discomfort
- Stay hydrated: Adequate hydration reduces headache and dizziness frequency
For full dosing and injection technique, see our TB-500 injection guide.
Frequently Asked Questions
Injection site reactions (redness, swelling, itching), temporary fatigue, headache, and mild dizziness. These typically resolve within a few hours and are more common at higher doses.
No clinical evidence in healthy individuals. The theoretical concern is that TB-500's angiogenic effect could support existing tumours. It is contraindicated in anyone with active or suspected cancer.
Both have mild profiles. TB-500 has slightly more reports of fatigue and immune modulation. BPC-157 has fewer angiogenesis concerns. Neither has long-term human safety data.
Pregnant or breastfeeding individuals, anyone with active or suspected cancer, those with hypersensitivity to peptide injections, people with autoimmune conditions, and those with cardiac conditions sensitive to fluid retention.
Start at 2mg twice per week, rotate injection sites, use 30–31 gauge needles, verify product purity (HPLC ≥98%), inject at room temperature, and stay well hydrated.
Stop immediately and seek emergency care. In Dubai, call 998 (ambulance) or go to the nearest hospital emergency department. Signs of severe reaction: widespread hives, face/throat swelling, breathing difficulty, chest pain.
CoreSup stocks pharmaceutical-grade bacteriostatic water (10ml, 0.9% benzyl alcohol) with same-day delivery across Dubai and all UAE emirates.
Shop Bacteriostatic Water →Related Products
Written by Amir Arsalan
Core Sup Research Team · Peptide & Supplement Specialists, Dubai UAE
Core Sup's editorial team is composed of specialists in peptide therapy, SARMs, and sports supplementation with direct experience in the UAE market. All content is written to current research standards and reviewed before publication.
Last reviewed: March 2026 · About Core Sup
